STOCK TITAN

Marker Therapeutics (MRKR) DEF 14A Filings

MRKR NASDAQ

Here are the DEF 14A proxy statements from Marker Therapeutics, Inc. (MRKR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRKR filings page.

Rhea-AI Summary

Marker Therapeutics is asking stockholders to vote at its May 1, 2026 virtual annual meeting on a broad set of governance and capital structure items. Stockholders will elect five directors, hold an advisory vote on executive pay, and ratify CBIZ as auditor for 2026.

A key proposal would amend the Certificate of Incorporation to increase authorized common stock from 30,000,000 to 130,000,000 shares, which could support future capital raising, equity incentives, or strategic transactions and may dilute existing holders if issued. Another proposal would lower the voting threshold for future changes to authorized share amounts or reverse splits to a majority of votes cast, aligning with recent Delaware law.

Stockholders will also vote on an adjournment proposal that would allow the meeting to be postponed to solicit more support for the share‑increase amendment if needed. The proxy describes board independence, committee structures, diversity, and compensation for President and CEO Juan Vera, M.D., who received $741,190 in total 2025 compensation.